Market Cap 1.32B
Revenue (ttm) 358.71M
Net Income (ttm) 23.39M
EPS (ttm) N/A
PE Ratio 13.82
Forward PE N/A
Profit Margin 6.52%
Debt to Equity Ratio 0.69
Volume 852,019
Avg Vol 834,032
Day's Range N/A - N/A
Shares Out 62.78M
Stochastic %K 7%
Beta 0.37
Analysts Strong Sell
Price Target $55.00

Company Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 238 9600
Address:
1350 Old Bayshore Highway, Suite 400, Burlingame, United States
All4Retiring
All4Retiring Jun. 12 at 2:17 PM
$INVA IMO INVA should be a buyout target. Zevtera (just launched) and Zoliflodacin (priority fda application filed) potential market cap is $800 million. INVA total market cap $1.36 Billion
2 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 11:21 AM
$INVA Innoviva announces zoliflodacin NDA granted Priority Review by FDA Innoviva announced that the FDA has granted Priority Review for the New Drug Application for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15 under the PDUFA. It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA's decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades.
0 · Reply
davis8uni
davis8uni Jun. 10 at 11:10 AM
0 · Reply
DonCorleone77
DonCorleone77 Jun. 10 at 10:18 AM
$INVA Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin Innoviva Specialty Therapeutics, a subsidiary of Innoviva, in collaboration with the Global Antibiotic Research & Development Partnership, announced that the U.S. FDA has accepted its New Drug Application for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades.
0 · Reply
All4Retiring
All4Retiring Jun. 9 at 6:12 PM
$INVA Please send someone other than Pavel to the investor events. He is too hard to understand and has no sales ability. Company also needs to get more aggressive forecasting their key assets. Zevtera and Zoliflodacin have 800 million market caps combined. Please forecast aggressively to match their potential.
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Jun. 8 at 10:41 PM
$INVA $1.33B mc $XBI name breaking out of a decade-plus-wide base on volume thru key $20 level above freshly rising 10/40/80-week SMAs - Pct of all funds long is at 3-year highs & rising - Short Squeeze candidate with short float % firmly trending lower from 26% to 15% over the past 14 months TrendEdge.app/asset/INVA
0 · Reply
always_learning_
always_learning_ Jun. 3 at 7:16 PM
$INVA off the radar stock had suddenly started to fly! Somebody know something?
0 · Reply
Estimize
Estimize Jun. 3 at 11:00 AM
Wall St is expecting 0.43 EPS for $INVA Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/inva?chart=historical&metric_name=eps&utm_co
0 · Reply
Doozio
Doozio Jun. 3 at 12:36 AM
$INVA it was always 🐒🍌🧠⏰♾️
0 · Reply
PenkeTrading
PenkeTrading May. 30 at 12:40 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Innoviva Inc. Is that bullish or bearish? $INVA #Innoviva #RsiOverbought #NASDAQ
0 · Reply
Latest News on INVA
Innoviva to Participate in Upcoming Investor Conferences

Jun 3, 2025, 7:00 AM EDT - 20 days ago

Innoviva to Participate in Upcoming Investor Conferences


Innoviva: Underappreciated Strength In Hospital Therapeutics

Feb 23, 2025, 1:11 AM EST - 4 months ago

Innoviva: Underappreciated Strength In Hospital Therapeutics


Innoviva to Participate in the UBS Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 7 months ago

Innoviva to Participate in the UBS Global Healthcare Conference


10 stocks you can bet on being inflation-proof

Feb 28, 2024, 2:48 PM EST - 1 year ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN


Innoviva: A Lot Of Moving Parts

Oct 9, 2023, 1:48 PM EDT - 1 year ago

Innoviva: A Lot Of Moving Parts


Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 25, 2023, 4:52 PM EDT - 1 year ago

Innoviva Appoints Stephen Basso as Chief Financial Officer


FDA approves Innoviva's bacterial pneumonia treatment

May 23, 2023, 10:32 PM EDT - 2 years ago

FDA approves Innoviva's bacterial pneumonia treatment


Innoviva Announces Retirement of Board Chairman

Apr 28, 2023, 5:30 PM EDT - 2 years ago

Innoviva Announces Retirement of Board Chairman


Innoviva Stock Trading Halted Today

Apr 17, 2023, 9:00 AM EDT - 2 years ago

Innoviva Stock Trading Halted Today


All4Retiring
All4Retiring Jun. 12 at 2:17 PM
$INVA IMO INVA should be a buyout target. Zevtera (just launched) and Zoliflodacin (priority fda application filed) potential market cap is $800 million. INVA total market cap $1.36 Billion
2 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 11:21 AM
$INVA Innoviva announces zoliflodacin NDA granted Priority Review by FDA Innoviva announced that the FDA has granted Priority Review for the New Drug Application for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15 under the PDUFA. It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA's decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades.
0 · Reply
davis8uni
davis8uni Jun. 10 at 11:10 AM
0 · Reply
DonCorleone77
DonCorleone77 Jun. 10 at 10:18 AM
$INVA Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin Innoviva Specialty Therapeutics, a subsidiary of Innoviva, in collaboration with the Global Antibiotic Research & Development Partnership, announced that the U.S. FDA has accepted its New Drug Application for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades.
0 · Reply
All4Retiring
All4Retiring Jun. 9 at 6:12 PM
$INVA Please send someone other than Pavel to the investor events. He is too hard to understand and has no sales ability. Company also needs to get more aggressive forecasting their key assets. Zevtera and Zoliflodacin have 800 million market caps combined. Please forecast aggressively to match their potential.
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Jun. 8 at 10:41 PM
$INVA $1.33B mc $XBI name breaking out of a decade-plus-wide base on volume thru key $20 level above freshly rising 10/40/80-week SMAs - Pct of all funds long is at 3-year highs & rising - Short Squeeze candidate with short float % firmly trending lower from 26% to 15% over the past 14 months TrendEdge.app/asset/INVA
0 · Reply
always_learning_
always_learning_ Jun. 3 at 7:16 PM
$INVA off the radar stock had suddenly started to fly! Somebody know something?
0 · Reply
Estimize
Estimize Jun. 3 at 11:00 AM
Wall St is expecting 0.43 EPS for $INVA Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/inva?chart=historical&metric_name=eps&utm_co
0 · Reply
Doozio
Doozio Jun. 3 at 12:36 AM
$INVA it was always 🐒🍌🧠⏰♾️
0 · Reply
PenkeTrading
PenkeTrading May. 30 at 12:40 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Innoviva Inc. Is that bullish or bearish? $INVA #Innoviva #RsiOverbought #NASDAQ
0 · Reply
CHItraders
CHItraders May. 20 at 11:54 AM
$INVA Basilea And Innoviva Launch Zevtera In U.S. As First MRSA-Active Antibiotic Approved For Staph Bacteremia In Over A Decade
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 20 at 10:47 AM
WATCHLIST MAY 20 2025. $DVLT Datavault AI To Finalize Strategic Acquisition Of CompuSystems Assets; Deal Expected To Drive 2H 2025 Revenue And Contribute $15M - $20M To 2026 Revenue Target And Growth Opportunities For Both Acoustic And Data Divisions $SES Cantor Fitzgerald Initiates Coverage On SES AI with Overweight Rating, Announces Price Target of $2 $RDWR Radware And MAIRE Expand Partnership to Deliver AI-Powered Managed Security Services Globally $INVA Innoviva Announces U.S. Launch Of Zevtera, An FDA Approved Advanced Generation Cephalosporin For MRSA SAB Since 2006, To Treat Three Types of Bacterial Infections $EYEN Eyenovia Provides Updates On Potential Merger With Betaliq And Development Of The Optejet User Filled Device; Says Co's Continue To Negotiate A Binding Merger Agreement, Have Agreed To Extend The Binding Exclusivity Period Set Forth In The Letter Of Intent Until June 7, 2025
0 · Reply
DonCorleone77
DonCorleone77 May. 20 at 10:27 AM
$INVA Innoviva subsidiary announces U.S. commercial availability of ZEVTERA Innoviva Specialty Therapeutics, a subsidiary of Innoviva, announced the United States commercial availability of ZEVTERA, the newest addition to the company's growing antibiotic portfolio. ZEVTERA is the only U.S. FDA approved advanced-generation cephalosporin indicated to treat adult patients with Staphylococcus aureus bloodstream infection, including those with right-side endocarditis caused by methicillin-susceptible and methicillin-resistant isolates. ZEVTERA is the latest approved MRSA SAB therapy since 2006.
0 · Reply
History101
History101 May. 19 at 5:49 PM
$INVA as i understand it, INVA owns 80% of $ARMP. ARMP is up over 30% today. How is INVA basically flat so far today?
0 · Reply
History101
History101 May. 19 at 5:47 PM
$INVA 1,475 watching 5/19/2025
0 · Reply
Estimize
Estimize May. 12 at 11:03 AM
Wall St is expecting 0.43 EPS for $INVA Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/inva?chart=historical&metric_name=eps&utm_co
0 · Reply
All4Retiring
All4Retiring May. 7 at 9:45 PM
$INVA Earnings Release Link to INVA website https://investor.inva.com/node/20696/pdf
0 · Reply
Armonica423
Armonica423 May. 6 at 5:18 PM
$INVA CYDY
0 · Reply
Estimize
Estimize Apr. 15 at 11:18 PM
Wall St is expecting 0.29 EPS for $INVA Q1 [Reporting 04/23 AMC] http://www.estimize.com/intro/inva?chart=historical&metric_name=eps&utm_co
0 · Reply
Winning_calls
Winning_calls Mar. 31 at 3:05 AM
$INVA pick me up @ $18.25
0 · Reply
JRoon71
JRoon71 Mar. 18 at 2:47 PM
$AMRN Sarissa just sold another $38M of $INVA shares. His entire portfolio of stocks is down to $250M. That's down from it's peak of $1B 2 years ago.
4 · Reply
macroaxis
macroaxis Mar. 14 at 6:10 PM
$INVA - Innoviva maximum pain price is slips to -1.0 https://www.macroaxis.com/stock-options/INVA/Innoviva?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply